

**Supplemental Table S4.** Comparison of Clinical Characteristics at Re-Evaluation and 1 Year after Treatment Resumption in Long-Gap and Short-Gap Group

Variable	GH interruption >2 years				GH interruption ≤2 years			
	No.	At re-evaluation	One year after treatment resumption	<i>P</i> value	No.	At re-evaluation	One year after treatment resumption	<i>P</i> value
Body mass index, kg/m <sup>2</sup>	110	24.7±4.8	25.2±4.7	0.007	71	23.2±4.6	23.8±4.8	0.015
Body mass index Z-score	110	0.9±1.7	1.1±1.7	0.006	71	0.5±1.6	0.6±1.6	0.068
IGF-1, µg/L	112	69.7±49.8	163.5±102.4	<0.001	69	94.5±87.9	172.8±136.7	<0.001
IGFBP-3, µg/L	80	1,752.4±624.7	2,256.5±881.9	<0.001	16	2,129.6±958.3	2,465.8±1,051.3	0.283
Fasting glucose, mg/dL	96	88.2±13.8	94.8±27.6	0.015	50	86.5±10.1	92.2±13.5	0.015
Glycated hemoglobin, %	63	5.5±0.6	5.6±0.8	0.286	31	5.3±0.5	5.5±1.2	0.366
Total cholesterol, mg/dL	106	187±34.8	189.6±41.5	0.525	59	177.5±28.6	174.7±32.1	0.383
Triglyceride, mg/dL	81	167.8±149.1	167.6±96.4	0.988	37	123.5±77.8	138.2±73.1	0.325
HDL cholesterol, mg/dL	43	41±12.6	48.2±14.5	<0.001	31	47.8±12.7	47.3±11.7	0.764
LDL cholesterol, mg/dL	43	122.8±37.2	114.6±35.5	0.127	31	110.5±22.1	108.8±26.7	0.688
Non-HDL cholesterol, mg/dL	43	150±34.2	139.7±38.4	0.123	31	130.2±25.7	129.5±23.7	0.857
Lumbar spine BMD Z-score	23	-1.9 (-2.7 to -1.2)	-1.9 (-2.5 to -0.9)	0.330	4	-2.1 (-3.2 to -0.5)	-1.6 (-2.8 to -0.6)	0.285
Femoral neck BMD Z-score	17	-1.7 (-2.2 to -1.0)	-1.0 (-2.0 to -0.2)	0.020	4	-1.8 (-2.8 to 0.7)	-0.9 (-2.8 to 0.5)	0.999

Values are expressed as mean ± standard deviation or median (interquartile range).

GH, growth hormone; IGF-1, insulin-like growth factor-1; IGFBP-3, IGF-binding protein-3; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BMD, bone mineral density.